Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12636573 | 0.84 | FPR2 (0.46) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL12636575 | 0.84 | FPR2 (0.46) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL9185808 | 0.83 | FPR2 (0.53) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL368204 | 0.80 | POLB (0.51) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL27523728 | 0.77 | FPR2 (0.47) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL2825741 | 0.77 | FPR2 (0.56) | FPR2GSK3AGSK3BALDH1A1MITF | |
| SCHEMBL13610873 | 0.77 | FPR2 (0.47) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL926457 | 0.76 | KMT2A (0.36) | FPR2ALDH1A1KDM4EPOLBKMT2A | |
| SCHEMBL16607297 | 0.75 | ALDH1A1 (0.46) | FPR2GSK3AGSK3BALDH1A1KDM4E | |
| SCHEMBL21539521 | 0.75 | FPR2 (0.54) | FPR2GSK3AGSK3BMITFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541580-B2 | Process for the preparation of pyrazinone thrombin inhibitor and its intermediates | DIAKRON PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541580-B2 | Process for the preparation of pyrazinone thrombin inhibitor and its intermediates | DIAKRON PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2011056806-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | DIAKRON PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105753-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | DIAKRON PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105753-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | DIAKRON PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-7026324-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| WO-2005040137-A1 | AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20040097730-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1359913-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6610692-B1 | Anticoagulants | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003011222-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1259506-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002064140-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6387911-B1 | Pyrazinone thrombin inhibitors | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001038323-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097730-A1 | Thrombin inhibitors | F3, F2, SERPINC1 | FPR2 446/4885GSK3A 2211/4885GSK3B 1826/4885 |
| US-20110105753-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | TFPI, TFPI2, F2 | FPR2 678/4885GSK3A 3238/4885GSK3B 3138/4885 |
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | FPR2 466/4885GSK3A 2042/4885GSK3B 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.